Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis

What is it about?

By meta-analysis, we find that long-acting GLP-1 receptor agonists better reduce HbA1c, fasting plasma glucose, and body weight, when added to basal insulin treatment, in comparison to short-acting compounds, at a lower risk for gastro-intestinal side effects and hypoglycemia.

Featured Image